Is Nuvation Bio Inc. (NYSE:NUVB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Nuvation Bio Inc. at current levels.
IBTROZI is a real launch hiding inside a $1.6B market cap, and the second pipeline shot keeps the upside alive.
Where NUVB is headed
Nuvation walked into 2026 as a one-product oncology company with a launched ROS1 inhibitor and a market cap that still treats it like a binary trial readout is coming. That mismatch is the whole story. IBTROZI (taletrectinib) is now in the hands of US thoracic oncologists, going head to head with Roche's Rozlytrek and Pfizer's Xalkori in a niche but defensible ROS1+ NSCLC segment of roughly 2,000-3,000 new addressable US patients a year, with a similar pool ex-US through the Innovent partnership in China. The clinical profile, deeper CNS penetration, cleaner neurological tolerability than entrectinib, durable responses post-crizotinib, gives reps something concrete to sell. With revenue growth running over 2,500% off a near-zero base and gross margin already above 90%, the operating question for the next eight quarters is straightforward: how fast does the script curve bend, and can they hit a US run-rate north of $200-300m by late 2027 without burning the balance sheet to do it.
Read the full Compass Direction on NUVB
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.51).
See the full NUVB analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Nuvation Bio Inc. (NYSE:NUVB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Nuvation Bio Inc. at current levels. IBTROZI is a real launch hiding inside a $1.6B market cap, and the second pipeline shot keeps the upside alive.
What is NUVB's Compass Score?
Nuvation Bio Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for NUVB?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NUVB page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.